12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Phase II data

Researchers at Hospices Civils de Lyon and colleagues reported data from the open-label, French Phase II METAFORE trial in 24 evaluable patients with HTT showing that Avastin significantly reduced mean cardiac output at 3 months after the first injection, the primary endpoint, to 4.2 L/min/m 2 from 5.01 L/min/m 2 at the start of treatment (p<0.001). At 6 months, Avastin also significantly reduced the endpoint from the start of treatment to 4.06 L/min/m 2. Additionally, Avastin led to a complete response, defined as normalization of cardiac output, in 3 patients...

Read the full 426 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >